Trace Neuroscience

Trace Neuroscience, Inc. is a biotechnology company developing genetic medicines for neurodegenerative diseases. Its lead investigational medicine, TRCN-1023, is designed to restore the function of the UNC13A protein, which is disrupted in most people living with amyotrophic lateral sclerosis (ALS). The company sponsors the FUNCtion ALS Phase 1/2 trial (NCT07674667) evaluating TRCN-1023 delivered by intrathecal injection. Trace Neuroscience is backed by GV and does not currently publish a public developer portal or APIs.

Trace Neuroscience is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Neuroscience, and ALS.

🌐 Visit website 📡 Source on GitHub

13.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyLife SciencesBiotechnologyNeuroscienceALSTherapeuticsClinical Trials

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 13.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/trace-neuroscience: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: trace-neuroscience
name: Trace Neuroscience
description: Trace Neuroscience, Inc. is a biotechnology company developing genetic medicines for neurodegenerative diseases.
  Its lead investigational medicine, TRCN-1023, is designed to restore the function of the UNC13A protein, which is disrupted
  in most people living with amyotrophic lateral sclerosis (ALS). The company sponsors the FUNCtion ALS Phase 1/2 trial (NCT07674667)
  evaluating TRCN-1023 delivered by intrathecal injection. Trace Neuroscience is backed by GV and does not currently publish
  a public developer portal or APIs.
url: https://raw.githubusercontent.com/api-evangelist/trace-neuroscience/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.traceneuro.com/wp-content/uploads/2024/09/piano.jpg
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Life Sciences
- Biotechnology
- Neuroscience
- ALS
- Therapeutics
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.traceneuro.com
- type: PrivacyPolicy
  url: https://www.traceneuro.com/privacy-policy/
- type: TermsOfService
  url: https://www.traceneuro.com/terms-of-service/
- type: DomainSecurity
  url: security/trace-neuroscience-domain-security.yml
- type: LLMsTxt
  url: llms/trace-neuroscience-llms.txt
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 2
  pass: local-v1